ADJUVANT CHEMOTHERAPY IN RESECTED NSCLC: TREATMENT FACTORS THAT IMPACT SURVIVAL OUTCOMES

被引：0
|
作者：
Ramsden, K. [1 ]
Laskin, J. [1 ]
Ho, C. [1 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2014年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
76P
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [31] Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Kato, Terufumi
    Laktionov, Konstantin
    Vu, Huu Vinh
    Wang, Zhijie
    Lu, Shun
    Lee, Kye Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Atasoy, Ajlan
    Herbst, Roy S.
    Tsuboi, Masahiro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 423 - 433
  • [32] Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity
    Wood, S.
    Li, R.
    Beesley, S.
    Brown, J.
    Cominos, M.
    Hall, J.
    Sevitt, T.
    Shah, R.
    Taylor, H.
    Burcombe, R.
    [J]. LUNG CANCER, 2015, 87 : S26 - S26
  • [33] Survival Benefit of Adjuvant Chemotherapy in Resected Squamous Carcinoma of the Gallbladder
    Olecki, Elizabeth
    Brahmbhatt, Rushin
    Peng, June
    Vining, Charles
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S192 - S192
  • [34] The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study
    Eralp, Y.
    Ak, N.
    Yilmazbayhan, D.
    Ozkan, B.
    Ferhatoglu, F.
    Demirkazik, A.
    Sak, S. Dizbay
    Dilege, S.
    Tanju, S.
    Toker, A.
    Bulutay, P.
    Firat, P.
    Mandel, N. Molinas
    Kilickap, S.
    Onder, S.
    Dikmen, E.
    Alan, O.
    Yumuk, P. F.
    Bozkurtlar, E.
    Lacin, T.
    Ozturk, A.
    Kocaturk, C.
    Karapinar, K.
    Urer, N.
    Uluc, B. Oyan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S892 - S893
  • [35] Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
    Bin Qiu
    Wei Guo
    Fan Zhang
    Fang Lv
    Ying Ji
    Yue Peng
    Xiaoxi Chen
    Hua Bao
    Yang Xu
    Yang Shao
    Fengwei Tan
    Qi Xue
    Shugeng Gao
    Jie He
    [J]. Nature Communications, 12
  • [36] Long-Term Results of Adjuvant Chemotherapy in Completely Resected NSCLC Patients
    Wurstbauer, Karl
    Sedlmayer, Felix
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (07) : 404 - 405
  • [37] Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
    Qiu, Bin
    Guo, Wei
    Zhang, Fan
    Lv, Fang
    Ji, Ying
    Peng, Yue
    Chen, Xiaoxi
    Bao, Hua
    Xu, Yang
    Shao, Yang
    Tan, Fengwei
    Xue, Qi
    Gao, Shugeng
    He, Jie
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [38] Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC
    Sorensen, Steffen Filskov
    Carus, Andreas
    Meldgaard, Peter
    [J]. LUNG CANCER, 2015, 88 (02) : 167 - 173
  • [39] Adjuvant Chemotherapy With Modified Nab-Paclitaxel and Carboplatin for Completely Resected NSCLC: Survival Analysis of FAST-Nab.
    Saji, H.
    Sakai, H.
    Kimura, H.
    Miyazawa, T.
    Marushima, H.
    Kojima, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S243 - S243
  • [40] SURVIVAL OUTCOMES FOLLOWING ADJUVANT FLUOROPYRIMIDINE-CONTAINING CHEMOTHERAPY FOR RESECTED EARLY STAGE RECTAL ADENOCARCINOMA
    Tay, Rebecca Y.
    Jamnagerwalla, Murtaza
    Steel, Malcolm
    Wong Hui-Li
    McKendrick, Joe J.
    Faragher, Ian
    Kosminder, Suzanne
    Hastie, Ian
    Desai, Jayesh
    Harold, Michael
    Gibbs, Peter
    Wong, Rachel
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 106 - 106
12345